Literature DB >> 24530755

Genetic polymorphism of interleukin-6 influences susceptibility to HBV-related hepatocellular carcinoma in a male Chinese Han population.

Shengli Tang1, Yufeng Yuan1, Yueming He1, Dingyu Pan1, Yongxi Zhang2, Yuanyuan Liu3, Quanyan Liu1, Zhonglin Zhang1, Zhisu Liu4.   

Abstract

As a multifunctional cytokine, interleukin-6 (IL-6) plays a key role in chronic inflammation as well as tumor growth and progression of hepatitis B virus (HBV) infection. Recent studies have implicated that single nucleotide polymorphism (SNP) -572C>G (rs1800796) located within the promoter region of IL-6 gene was associated with susceptibility to several diseases. Here, a case-control study was undertaken to investigate the association between this polymorphism and HBV-related hepatocellular carcinoma (HCC) susceptibility in a Chinese Han population. A total of 900 patients with chronic HBV infection, including 505 HBV-related HCC patients and 395 HBV infected patients without HCC were enrolled, and rs1800796 polymorphism was genotyped by the TaqMan method and DNA sequencing technology. The results indicated no significant association between rs1800796 polymorphism and the risk of HBV-related HCC in all subjects; however, a significant difference was identified in male subjects. Under the dominant model, male subjects with the G allele (CG/GG) have higher susceptibility to HBV-related HCC than those with CC genotype after adjusting confounding factors (P=0.012, odds ratio [OR] 1.68, 95% confidence interval [95% CI] 1.15-2.42). Our results suggested that rs1800796 polymorphism of IL-6 gene was associated with susceptibility to HBV-related HCC in a male Chinese Han population.
Copyright © 2014 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24530755     DOI: 10.1016/j.humimm.2014.02.006

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  14 in total

1.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.

Authors:  Pengyuan Yang; Geoffrey J Markowitz; Xiao-Fan Wang
Journal:  Natl Sci Rev       Date:  2014-07-14       Impact factor: 17.275

Review 2.  Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms.

Authors:  Mahmoud Fathy Dondeti; Eman Anwar El-Maadawy; Roba Mohamed Talaat
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

3.  Interleukin-6 gene variants are associated with reduced risk of chronicity in hepatitis B virus infection in a Malaysian population.

Authors:  Behnaz Riazalhosseini; Zahurin Mohamed; Yamunah Devi Apalasamy; Noor Shafila Shafie; Rosmawati Mohamed
Journal:  Biomed Rep       Date:  2018-07-09

4.  Association between IL-6 Gene (-174 & -572 G/C) Polymorphisms and Endometrial Adenocarcinoma Risk.

Authors:  Hai-Ying Wang; Jin-Jun Zhang; Xiang-Yu Zheng; Jian-Hua Liu; Yong-Wei Li
Journal:  Pathol Oncol Res       Date:  2016-05-19       Impact factor: 3.201

5.  IL6 gene allele-specific C/EBPα-binding activity affects the development of HBV infection through modulation of Th17/Treg balance.

Authors:  G Zhang; W Wang; S Li; H Yang; M Zhang; P Zhang; Y Wen; A Wu; L Yang; B Zhou; X Chen
Journal:  Genes Immun       Date:  2015-10-08       Impact factor: 2.676

6.  Gene copy number variations in the leukocyte genome of hepatocellular carcinoma patients with integrated hepatitis B virus DNA.

Authors:  Yanan Pang; Weixing Guo; Jiaqi Wang; Guixia Xu; Kai Cheng; Guangwen Cao; Mengchao Wu; Shuqun Cheng; Shanrong Liu
Journal:  Oncotarget       Date:  2016-02-16

7.  Interleukin-6 (IL-6) rs1800796 and cyclin dependent kinase inhibitor (CDKN2A/CDKN2B) rs2383207 are associated with ischemic stroke in indigenous West African Men.

Authors:  Rufus Akinyemi; Donna K Arnett; Hemant K Tiwari; Bruce Ovbiagele; Fred Sarfo; Vinodh Srinivasasainagendra; Marguerite Ryan Irvin; Abiodun Adeoye; Rodney T Perry; Albert Akpalu; Carolyn Jenkins; Lukman Owolabi; Reginald Obiako; Kolawole Wahab; Emmanuel Sanya; Morenikeji Komolafe; Michael Fawale; Philip Adebayo; Godwin Osaigbovo; Taofiki Sunmonu; Paul Olowoyo; Innocent Chukwuonye; Yahaya Obiabo; Onoja Akpa; Sylvia Melikam; Raelle Saulson; Raj Kalaria; Adesola Ogunniyi; Mayowa Owolabi
Journal:  J Neurol Sci       Date:  2017-05-23       Impact factor: 3.181

Review 8.  Generic chemoprevention of hepatocellular carcinoma.

Authors:  Sai Krishna Athuluri-Divakar; Yujin Hoshida
Journal:  Ann N Y Acad Sci       Date:  2018-09-17       Impact factor: 6.499

9.  Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.

Authors:  Peng-Yuan Zhuang; Jian-Dong Wang; Zhao-Hui Tang; Xue-Ping Zhou; Zhi-Wei Quan; Ying-Bin Liu; Jun Shen
Journal:  BMC Cancer       Date:  2015-11-02       Impact factor: 4.430

10.  Effect of TALEN-mediated IL-6 knockout on cell proliferation, apoptosis, invasion and anti-cancer therapy in hepatocellular carcinoma (HCC-LM3) cells.

Authors:  Peng-Yuan Zhuang; Ke-Wei Zhang; Jian-Dong Wang; Xue-Ping Zhou; Ying-Bin Liu; Zhi-Wei Quan; Jun Shen
Journal:  Oncotarget       Date:  2017-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.